Alice E. Toll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alice E. Toll has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Wida S. Cherikh
The International Society for Heart and Lung Transplantation Thoracic Organ Transplant Registry, Chicago, IL
2 shared publications A. Koliopolou
Cardiothoracic Surgery, University of Utah, Salt Lake City, UT
1 shared publicationA.G. Kfoury
Intermountain Healthcare, Salt Lake City, UT
1 shared publication- Aijaz Ahmed
Division of Gastroenterology and Hepatology Stanford University School of Medicine Stanford California USA
1 shared publication - Alexandra Lewis
The International Society for Heart and Lung Transplantation Thoracic Organ Transplant Registry, Chicago, IL
1 shared publication - Amanda Klein
Critical Path Institute, Tucson, AZ, USA
1 shared publication
Latest Publications
- Open Access
- 3 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (3) , e042320
Impact of Peak Donor Troponin and Donor Troponin Trends on Pediatric Heart Transplant Outcomes
Background: Donor discard rates for pediatric heart transplant (HT) remain high (≈40%), often driven by concerns about elevated donor troponin levels. This study evaluated the association between peak donor troponin levels, donor troponin trends, and post transplant survival among pediatric HT recipients. Methods: Children (aged P P =0.045). Troponin trends were not associated with post‐HT graft survival. Conclusions: Most pediatric HT donors exhibit abnormal troponin levels. Elevated peak donor troponin (>0.66 ng/mL) correlates with donor hemodynamic instability and predicts worse 1‐year post transplant graft survival, whereas troponin trajectories are not prognostic.
- 3 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (3) , e042320
Open AccessImpact of Peak Donor Troponin and Donor Troponin Trends on Pediatric Heart Transplant Outcomes
Background: Donor discard rates for pediatric heart transplant (HT) remain high (≈40%), often driven by concerns about elevated donor troponin levels. This study evaluated the association between peak donor troponin levels, donor troponin trends, and post transplant survival among pediatric HT recipients. Methods: Children (aged P P =0.045). Troponin trends were not associated with post‐HT graft survival. Conclusions: Most pediatric HT donors exhibit abnormal troponin levels. Elevated peak donor troponin (>0.66 ng/mL) correlates with donor hemodynamic instability and predicts worse 1‐year post transplant graft survival, whereas troponin trajectories are not prognostic.
- Open Access
- 1 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5441
Donor–Recipient Race Mismatch Is Associated with Lower Survival After Liver Transplantation for Primary Sclerosing Cholangitis
Background: Patient survival after liver transplantation is lower in donor–recipient race mismatched patients for indications other than primary sclerosing cholangitis. Objectives: To determine if survival is lower after liver transplantation in donor–recipient race mismatched recipients with primary sclerosing cholangitis. Methods: The Organ Procurement and Transplantation Network database was analyzed for deceased donor adult liver transplant recipients with primary sclerosing cholangitis. Graft and patient survival by donor–recipient race were estimated using Kaplan–Meier survival method and compared using the log-rank test. Multivariable analysis was performed using Cox regression. Results: From 2002 to 2018, 5-year patient survival in White (n = 2223) and Black recipients (n = 491), was 89.8% and 87.1%, respectively. Five-year patient survival for the donor–recipient pairs, White–White (n = 1622), Black–Black (n = 110), Black–White (n = 335), and White–Black (n = 314) was 90.8%, 91.1%, 87.1%, and 86.0%, respectively, p = 0.026. In multivariable analysis, 5-year patient mortality was higher in Black recipients of White donors [HR 1.69, 95% CI 1.16, 2.45], compared to White recipients of White donors. Conclusions: Five-year patient mortality after deceased donor liver transplantation for primary sclerosing cholangitis is higher in Black recipients who received livers from White donors compared to matched White donors and recipients.
- 1 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5441
Open AccessDonor–Recipient Race Mismatch Is Associated with Lower Survival After Liver Transplantation for Primary Sclerosing Cholangitis
Background: Patient survival after liver transplantation is lower in donor–recipient race mismatched patients for indications other than primary sclerosing cholangitis. Objectives: To determine if survival is lower after liver transplantation in donor–recipient race mismatched recipients with primary sclerosing cholangitis. Methods: The Organ Procurement and Transplantation Network database was analyzed for deceased donor adult liver transplant recipients with primary sclerosing cholangitis. Graft and patient survival by donor–recipient race were estimated using Kaplan–Meier survival method and compared using the log-rank test. Multivariable analysis was performed using Cox regression. Results: From 2002 to 2018, 5-year patient survival in White (n = 2223) and Black recipients (n = 491), was 89.8% and 87.1%, respectively. Five-year patient survival for the donor–recipient pairs, White–White (n = 1622), Black–Black (n = 110), Black–White (n = 335), and White–Black (n = 314) was 90.8%, 91.1%, 87.1%, and 86.0%, respectively, p = 0.026. In multivariable analysis, 5-year patient mortality was higher in Black recipients of White donors [HR 1.69, 95% CI 1.16, 2.45], compared to White recipients of White donors. Conclusions: Five-year patient mortality after deceased donor liver transplantation for primary sclerosing cholangitis is higher in Black recipients who received livers from White donors compared to matched White donors and recipients.
- Open Access
- 11 October 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (2) , 250-259
Applying propensity methods to the United States transplant registry for external real-world evidence control arms for 5-year survival in the BENEFIT study
- 11 October 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (2) , 250-259
Open AccessApplying propensity methods to the United States transplant registry for external real-world evidence control arms for 5-year survival in the BENEFIT study
- 1 April 2019
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 38 (4) , S109-S110
Predictors of Favorable Outcome in Patients Bridged to Transplant with Temporary Mechanical Circulatory Support Devices
- 1 April 2019
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 38 (4) , S109-S110
Predictors of Favorable Outcome in Patients Bridged to Transplant with Temporary Mechanical Circulatory Support Devices
- Open Access
Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era
In recent years, the opioid epidemic and new hepatitis C virus (HCV) treatments have changed the landscape of organ procurement and allocation. We studied national trends in solid organ transplantation (2000–2016), focusing on graft utilization from HCV seropositive deceased donors in the pre-2014 (2000–2013) versus current (2014–2016) eras with a retrospective analysis of the United Network for Organ Sharing database. During the study period, HCV seropositive donors increased from 181 to 661 donors/year. The rate of HCV seropositive donor transplants doubled from 2014 to 2016. Heart and lung transplantation data were too few to analyze. A higher number of HCV seropositive livers were transplanted into HCV seropositive recipients during the current era: 374 versus 124 liver transplants/year. Utilization rates for liver transplantation reached parity between HCV seropositive and non-HCV donors. While the number of HCV seropositive kidneys transplanted to HCV seropositive recipients increased from 165.4 to 334.7 kidneys/year from the pre-2014 era to the current era, utilization rates for kidneys remained lower in HCV seropositive than in non-HCV donors. In conclusion, relative underutilization of kidneys from HCV seropositive versus non-HCV donors has persisted, in contrast to trends in liver transplantation.
Open AccessUnderutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era
In recent years, the opioid epidemic and new hepatitis C virus (HCV) treatments have changed the landscape of organ procurement and allocation. We studied national trends in solid organ transplantation (2000–2016), focusing on graft utilization from HCV seropositive deceased donors in the pre-2014 (2000–2013) versus current (2014–2016) eras with a retrospective analysis of the United Network for Organ Sharing database. During the study period, HCV seropositive donors increased from 181 to 661 donors/year. The rate of HCV seropositive donor transplants doubled from 2014 to 2016. Heart and lung transplantation data were too few to analyze. A higher number of HCV seropositive livers were transplanted into HCV seropositive recipients during the current era: 374 versus 124 liver transplants/year. Utilization rates for liver transplantation reached parity between HCV seropositive and non-HCV donors. While the number of HCV seropositive kidneys transplanted to HCV seropositive recipients increased from 165.4 to 334.7 kidneys/year from the pre-2014 era to the current era, utilization rates for kidneys remained lower in HCV seropositive than in non-HCV donors. In conclusion, relative underutilization of kidneys from HCV seropositive versus non-HCV donors has persisted, in contrast to trends in liver transplantation.